8 results about "Hepatitis E" patented technology

The invention discloses application of PYGL as an auxiliary diagnosis marker for hepatitis E related acute hepatic failure, and belongs to the technical field of biomedical detection. By detecting the expression level of PYGL in serum of a subject, hepatitis E related acute hepatic failure patients (HEV-ALF), acute hepatitis E patients (AHE) and healthy control people (HCs) can be effectively distinguished. The result shows that the serum PYGL expression level of HEV-ALF patients is obviously higher than that of acute hepatitis E patients and healthy control people; the serum PYGL expression level has significant correlation with the clinical outcome of patients with hepatitis E related acute hepatic failure, and the serum PYGL expression level of patients in a death group is significantly higher than that of patients in a survival group; the expression level of the serum PYGL is also associated with the number of organ failure of the patient, and can reflect the dynamic change of the condition of the patient. Therefore, the serum PYGL can be used as an effective biomarker for auxiliary diagnosis of the hepatitis E related acute hepatic failure and prognosis evaluation of the hepatitis E related acute hepatic failure.

The application provides mRNA based on HEV ORF2 truncated protein, a preparation method and application thereof, the mRNA based on HEV ORF2 truncated protein includes 5'UTR region, SP fragment, 3'UTR region, 3' terminal poly A tail, gene for encoding hepatitis E virus ORF2 truncated protein and 5' cap structure, the hepatitis E virus ORF2 truncated protein is ORF2-239aa protein or ORF2-549aa protein, the nucleotide sequence of the gene for encoding the ORF2-239aa protein is shown as SEQ ID NO.1, the nucleotide sequence of the gene for encoding the ORF2-549aa protein is shown as SEQ ID NO.2, the application has application value in hepatitis E research and vaccine creation, and can greatly promote the transformation application of vaccine.

Virus-Like Particles derived from the subfamilies, Parahepevirinae, which infect trout and salmon, and the Orthohepevirinae, which infect mammals and birds, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are also disclosed. Major aspects of the invention relate to compositions of Virus-Like Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus-Like Particles. Preferred aspects relate to functional capsids comprising polypeptide sequences comprising one or more amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, wherein said variant polypeptides are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV). Other aspects include the design and assembly of modified vectors to facilitate the basic and applied studies leading to the development and commercialization of novel drug products, and as tools advancing the interests of institutions involved in animal and human healthcare.

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The invention belongs to the technical field of vaccines, and particularly relates to a hepatitis E virus recombinant circular RNA (Ribonucleic Acid) nanoparticle vaccine taking MS2 bacteriophage pseudovirus particles as a packaging carrier and a construction method of the hepatitis E virus recombinant circular RNA nanoparticle vaccine. The construction method of the hepatitis E virus recombinant circular RNA nanoparticle vaccine successfully constructs a novel hepatitis E circular RNA vaccine taking MS2 phage pseudovirion as a carrier, and provides a new thought for research, development and application of the hepatitis E vaccine. According to the method, on the basis of combined application of an armored RNA technology and a Clean-PIE technology, HEVp239 annular mRNA vaccine particles are delivered, and a nanoparticle molecular vaccine is specifically combined with a PAC aptamer sequence embedded in an annular RNA (circRNA) molecule through a PAC binding site on the inner surface of an MS2 phage pseudovirus particle, so that the annular RNA is efficiently packaged and encapsulated in the particles; the MS2 dimerTATHis-HEV circRNA nanoparticle vaccine is formed, and a new technical thought and method are provided for prevention and control of hepatitis E.

Virus-Like Particles derived from the subfamilies, Parahepevirinae and Orthohepevirinae, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are disclosed. Compositions of VirusLike Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus- Like Particles are provided. Functional capsids comprising polypeptide sequences comprising amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, that are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV) are provided.

The invention provides a preparation method of a triple recombinant vaccine, which is mainly used for preparing rabbit hemorrhagic syndrome, rabbit hepatitis E and rabbit pox virus recombinant vaccines. The method comprises the following steps: extracting RHDV VP60 and HEV-ORF2 genes, constructing recombinant plasmids, transfecting the recombinant plasmids into competent cells, screening and identifying the recombinant plasmids, culturing the recombinant plasmids in rabbit kidney cells, amplifying after pressurizing and screening, harvesting recombinant viruses, repeatedly freezing and thawing, and freezing and storing. The purpose of preventing rabbit pox viruses, rabbit hepatitis E and rabbit viral syndromes is achieved by vaccination of rabbits, production is easy, the problem of cold storage does not exist, three viruses are prevented through one injection, meat body pain and local red and swollen caused by multiple injections to animals are avoided, and stress response is reduced. Meanwhile, the rabbit pox is a carrier of the species, so that the interference caused by a non-species carrier is reduced, the stimulation to inoculated animals is small, the immune effect is strong and the like, and the research of the rabbit pox carrier vaccine has wide theoretical significance and practical significance.

This application relates to bicyclic and monocyclic nucleoside analogs for the treatment of hepatitis E. The present disclosure relates to bicyclic and monocyclic nucleoside analogs for use in the treatment of hepatitis E infection, and compositions comprising these compounds.